Comparative Pharmacology
Head-to-head clinical analysis: BALSALAZIDE DISODIUM versus LIALDA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BALSALAZIDE DISODIUM versus LIALDA.
BALSALAZIDE DISODIUM vs LIALDA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Prodrug that delivers mesalamine (5-aminosalicylic acid) to the colon; mesalamine inhibits cyclooxygenase and lipoxygenase pathways, reducing prostaglandin and leukotriene synthesis, and scavenges reactive oxygen species, thereby decreasing colonic inflammation.
Mesalamine, the active ingredient in Lialda, is an anti-inflammatory agent that inhibits prostaglandin production and leukotriene synthesis, and reduces cytokine production in the colonic mucosa.
2.25 g (three 750 mg capsules) orally three times daily
2-4 tablets (2.4-4.8 g) orally once daily. Each tablet contains 1.2 g mesalamine.
None Documented
None Documented
Balsalazide itself has a terminal elimination half-life of approximately 0.5–1 hour; the active moiety mesalamine has a terminal half-life of 5–10 hours, which may be prolonged in renal impairment.
Terminal elimination half-life of mesalamine is approximately 12 hours (range 8-15 hours) for the sustained-release formulation; clinical steady-state is reached within 3-5 days.
Primarily excreted in feces via biliary elimination (approximately 90%) following conversion to mesalamine; renal excretion accounts for less than 10% of the dose as mesalamine and its metabolites.
Renal (primarily, as N-acetyl-5-aminosalicylic acid, about 80%) and fecal (as unchanged mesalamine, about 20%).
Category C
Category C
Aminosalicylate
Aminosalicylate